Novel antithrombotic agents, including low-molecular-weight heparin and glycoprotein IIb-IIIa inhibitors, are reviewed for the management of non-ST-segment elevation acute coronary syndromes.
This review provides an overview of the pathophysiology of NSTE ACS and the role of novel antithrombotic agents in its management according to ACC/AHA guidelines.
Our understanding of the pathophysiology of unstable angina (UA) and non-ST-segment elevation (NSTE) myocardial infarction (MI) commonly referred to as NSTE acute coronary syndrome(s) (ACS) has evolved considerably over the years, with atherothrombosis playing a pivotal role. This review discusses the molecular interactions in coronary thrombosis that may serve as therapeutic targets for more effective management of these syndromes. The purposes of this review are: 1) to discuss current understanding of the pathophysiology of NSTE ACS; 2) to describe recent studies with novel antithrombotic agents e.g., low-molecular-weight heparin, thienopyridines, glycoprotein (GP) IIb-IIIa inhibitors in patients with NSTE ACS; and 3) to highlight recommendations for management of patients with NSTE ACS in the recently updated American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines, including the appropriate use of antithrombotic therapies.
Gerard X. Brogan (Tue,) conducted a review in Non-ST-segment elevation acute coronary syndromes (NSTE ACS). Antithrombotic agents (e.g., low-molecular-weight heparin, thienopyridines, glycoprotein IIb-IIIa inhibitors) was evaluated. Novel antithrombotic agents, including low-molecular-weight heparin and glycoprotein IIb-IIIa inhibitors, are reviewed for the management of non-ST-segment elevation acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: